Affiliation:
1. Department of Psychiatry, Addiction Medicine Lausanne University Hospital and University of Lausanne Lausanne Switzerland
2. Department of Medicine, Section of General Internal Medicine, Clinical Addiction Research and Education (CARE) Unit Boston University School of Medicine and Boston Medical Center Boston Massachusetts USA
3. Department of Community Health Sciences Boston University School of Public Health Boston Massachusetts USA
4. Department of Epidemiology and Biostatistics University of California San Francisco San Francisco California USA
5. Department of Medicine University of California San Francisco San Francisco California USA
6. Department of Biostatistics Boston University School of Public Health Boston Massachusetts USA
7. Vanderbilt Center for Clinical Cardiovascular Trials Evaluation (V‐C3REATE) Vanderbilt University Medical Center, Cardiovascular Division Nashville Tennessee USA
8. Biostatistics and Epidemiology Data Analytics Center (BEDAC) Boston University School of Public Health Boston Massachusetts USA
9. HIV/AIDS Research National Institute on Alcohol Abuse and Alcoholism Bethesda Maryland USA
10. First Pavlov State Medical University of Saint Petersburg St. Petersburg Russia
11. Department of Internal Medicine Mbarara University of Science and Technology Mbarara Uganda
Abstract
AbstractBackgroundAlcohol use has been linked to worse human immunodeficiency virus (HIV) immunologic/virologic outcomes, yet few studies have explored the effects of alcohol use disorder (AUD). This study assessed whether AUD severity is associated with HIV viral suppression and CD4 count in the three cohorts of the Uganda Russia Boston Alcohol Network for Alcohol Research Collaboration on HIV/AIDS (URBAN ARCH) Consortium.MethodsPeople with HIV (PWH) in Uganda (n = 301), Russia (n = 400), and Boston (n = 251), selected in‐part based on their alcohol use, were included in analyses. Logistic and linear regressions were used to assess the cross‐sectional associations between AUD severity (number of DSM‐5 diagnostic criteria) and (1) HIV viral suppression, and (2) CD4 count (cells/mm3) adjusting for covariates. Analyses were conducted separately by site.ResultsThe proportion of females was 51% (Uganda), 34% (Russia), and 33% (Boston); mean age (SD) was 40.7 (9.6), 38.6 (6.3), and 52.1 (10.5), respectively. All participants in Uganda and all but 27% in Russia and 5% in Boston were on antiretroviral therapy. In Uganda, 32% met criteria for AUD, 92% in Russia, and 43% in Boston. The mean (SD) number of AUD criteria was 1.6 (2.4) in Uganda, 5.6 (3.3) in Russia, and 2.4 (3.1) in Boston. Most participants had HIV viral suppression (Uganda 92%, Russia 57%, Boston 87%); median (IQR) CD4 count was 673 (506, 866), 351 (201, 542), and 591 (387, 881), respectively. In adjusted models, there were no associations between AUD severity and HIV viral suppression: adjusted odds ratios (AOR) (95%CI) per 1 additional AUD criterion in Uganda was 1.08 (0.87, 1.33); Russia 0.98 (0.92, 1.04); and Boston 0.95 (0.84, 1.08) or CD4 count: mean difference (95%CI) per 1 additional criterion: 5.78 (−7.47, 19.03), −3.23 (−10.91, 4.44), and −8.18 (−24.72, 8.35), respectively.ConclusionsIn three cohorts of PWH, AUD severity was not associated with HIV viral suppression or CD4 count. PWH with AUD in the current era of antiretroviral therapy can achieve virologic control.
Funder
National Institute of Allergy and Infectious Diseases
National Institute on Alcohol Abuse and Alcoholism
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献